A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients

Not Applicable

Completed

• Conditions: Mycobacterium Avium-Intracellulare Infection; HIV Infections

• Registration Number: NCT00002309
• Lead Sponsor: Pfizer

Brief Summary

To evaluate the efficacy and safety of azithromycin administered once a week in the prevention of disseminated Mycobacterium avium complex (MAC) in severely immunocompromised HIV-infected patients with a CD4 count \< 100 cells/mm3.

Detailed Description

Not available

Study Timeline

• Status Verified: 1996-04
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (3)

United States Air Force Med Ctr; 🇺🇸 Lackland Air Force Base, Texas, United States

San Diego Naval Hosp; 🇺🇸 San Diego, California, United States

Womack Army Med Ctr / Med Clinic; 🇺🇸 Fort Bragg, North Carolina, United States